EMQN to introduce innovative EQA Scheme for MT-RNR1 POCT
As the healthcare landscape has begun to rely increasingly on the use of point-of-care testing at, or close to, the patient’s bedside, it is crucial to ensure those tests are accurate and reliable, since immediate clinical decisions are based on the outcomes where even the slightest error could have profound consequences. EMQN CIC has introduced […]
EMQN & SensID launch ctDNA extraction EQA scheme
EMQN CIC and SensID GmbH are pleased to announce a strategic partnership to deliver a new External Quality Assessment (EQA) / Proficiency Testing (PT) scheme for circulating tumour DNA (ctDNA) extraction from plasma. Background The use of molecular testing to aid in determining therapy options for the treatment of non-small cell lung cancer (NSCLC) is now […]
Introducing the new look EMQN strategy and brand
To consolidate our position as the leading global provider of quality assurance services and knowledge to the human molecular pathology and genetics testing community, we have refined our strategy and launched a distinctive new brand and website. Our aim with this is to better reach new laboratories that could benefit from our help, to help […]
EMQN join DEVOTE programme
EMQN CIC are delighted to be part of the DEVOTE programme, working with the partners (genedrive, Chromition, APIS Assay Technologies Ltd., Manchester University NHS Foundation Trust, Health Innovation Manchester) to deliver EQA for point-of-care testing in pharmacogenetics. Ensuring the delivery of high quality testing to support personalised treatment at the right time to improve patient […]
EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: State of the art 2023
[Correction added on 25 October 2023, after first online publication: Figure A1 has been replaced in this version.] Abstract Testing for AZoospermia Factor (AZF) deletions of the Y chromosome is a key component of the diagnostic workup of azoospermic and severely oligozoospermic men. This revision of the 2013 European Academy of Andrology (EAA) and EMQN […]
EMQN Best Practice Guidelines for Genetic Testing in Inherited Cardiomyopathies and Arrhythmias
Abstract Inherited cardiomyopathies and arrhythmias (ICAs) are a prevalent and clinically heterogeneous group of genetic disorders that are associated with increased risk of sudden cardiac death and heart failure. Making a genetic diagnosis can inform the management of patients and their at-risk relatives and, as such, molecular genetic testing is now considered an integral component […]